Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:15:28.235Z.
Calculation as of: 2026-10-06T14:15:28.235Z.
Quote observation: 2026-10-06T14:15:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79e645a94fbd5e366445fb8f0b2dfca38265e5d6ea8975ca37c6e7b4421e0c07
PE RATIO
N/A
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$109.64M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$107.45M
PE Ratio
N/A
TTM Avg
17.69
3Y Avg
17.69
5Y Avg
17.69
Market Cap
$106.83M
PE Ratio
N/A
TTM Avg
2144.18
3Y Avg
993.27
5Y Avg
551.35
Market Cap
$105.61M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $109.64M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.91M | N/A | 3.95 | 3.95 | 3.95 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $108.33M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $106.73M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.45M | N/A | 17.69 | 17.69 | 17.69 |
| BGM Group Ltd. (BGM)vs › | $112.03M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $112.13M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.83M | N/A | 2144.18 | 993.27 | 551.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $105.61M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.10M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$5.01
Forward EPS (Est.)
$-3.15
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
